Plasma-Derived Therapies Market: By Product (Immunoglobulins (IG – SCIG/IVIG), Albumin, Coagulation factors (blood factors – haemophilia), and Others), By Application (Primary Immunodeficiency Diseases (PID), Haemophilia, Idiopathic Thrombocytopenic Purpura (ITP), and Others), and Geography

Plasma-Derived Therapies Market size was valued at USD 31,728.9 million in 2023 and is projected to grow at 6.3% CAGR over the forecast years to reach USD 48,661.8 million by 2030. The plasma-derived therapies market is driven by factors such as the increasing prevalence of rare diseases, rising awareness of plasma-derived therapies, and advancements in manufacturing processes. There is a growing number of people being diagnosed with rare diseases, many of which can be treated with plasma-derived therapies. This includes conditions like primary immunodeficiency diseases, hemophilia, and idiopathic thrombocytopenic purpura (ITP). In the United States: The CDC estimates the prevalence of hemophilia to be around 12 cases per 100,000 males for hemophilia A and 3.7 cases per 100,000 males for hemophilia B Centers for Disease Control and Prevention. This translates to roughly 33,000 males living with hemophilia in the US Centers for Disease Control and Prevention. According to the World Federation of Hemophilia (WFH) survey report 2022, globally, the mean estimated prevalence is 17.1 per 100,000 males for all hemophilia A and 6.0 per 100,000 males for severe hemophilia A. The global mean estimated prevalence is 3.8 per 100,000 males for all hemophilia B and 1.1 per 100,000 males for severe hemophilia B. It's important to note that hemophilia primarily affects people assigned male at birth. Females can carry the hemophilia gene, but they usually don't experience symptoms themselves. However, they have a 50% chance of passing the gene on to their sons.

As more people become aware of the benefits of plasma-derived therapies, demand for these treatments is expected to increase, and improvements in plasma fractionation techniques are leading to the development of more pure and effective plasma-derived therapies. Despite the positive outlook, the constraints of the market will hinder the market growth such factors as a limited supply of plasma, high cost of plasma-derived therapies, and regulatory hurdles. Development of new plasma-derived therapies, expansion into new markets, and increased focus on plasma collection are opportunities and personalized medicine, home infusion, and emerging markets are the trends in the plasma-derived therapies market.

Plasma-Derived Therapies Market Key Developments:

• In October 202, BioLife Plasma Services, a part of the Japanese biopharmaceutical company Takeda, opened its first Massachusetts plasma center in Worcester. The new facility, located at 68 Stafford St., was established to address the increasing need for plasma, which is essential for producing life-saving plasma-based therapies.
• In July 2020, Grifols, a leading manufacturer of plasma-derived medications, signed a contract to acquire the plasma fractionation facility in Montreal, as well as other plasma collection sites in the US and two purifying facilities.